Membership
Tour
Register
Log in
Reverse Transcribing DNA Viruses
Follow
Industry
CPC
C12N2730/00
This industry / category may be too specific. Please go to a parent level for more data
Parent Industries
C
CHEMISTRY METALLURGY
C12
Biochemistry
C12N
MICRO-ORGANISMS OR ENZYMES COMPOSITIONS THEREOF PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS MUTATION OR GENETIC ENGINEERING CULTURE MEDIA
Current Industry
C12N2730/00
Reverse Transcribing DNA Viruses
Sub Industries
C12N2730/00011
Reverse Transcribing DNA Viruses
C12N2730/00021
Viruses as such
C12N2730/00022
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2730/00023
Virus like particles [VLP]
C12N2730/00031
Uses of virus other than therapeutic or vaccine
C12N2730/00032
Use of virus as therapeutic agent, other than vaccine
C12N2730/00033
Use of viral protein as therapeutic agent other than vaccine
C12N2730/00034
Use of virus or viral component as vaccine
C12N2730/00041
Use of virus, viral particle or viral elements as a vector
C12N2730/00042
virus or viral particle as vehicle
C12N2730/00043
viral genome or elements thereof as genetic vector
C12N2730/00044
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N2730/00045
Special targeting system for viral vectors
C12N2730/00051
Methods of production or purification of viral material
C12N2730/00052
relating to complementing cells and packaging systems for producing virus or viral particles
C12N2730/00061
Methods of inactivation or attenuation
C12N2730/00062
by genetic engineering
C12N2730/00063
by chemical treatment
C12N2730/00064
by serial passage
C12N2730/00071
Demonstrated in vivo effect
C12N2730/00088
For redistribution
C12N2730/10011
Hepadnaviridae
C12N2730/10021
Viruses as such
C12N2730/10022
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2730/10023
Virus like particles [VLP]
C12N2730/10031
Uses of virus other than therapeutic or vaccine
C12N2730/10032
Use of virus as therapeutic agent, other than vaccine
C12N2730/10033
Use of viral protein as therapeutic agent other than vaccine
C12N2730/10034
Use of virus or viral component as vaccine
C12N2730/10041
Use of virus, viral particle or viral elements as a vector
C12N2730/10042
virus or viral particle as vehicle
C12N2730/10043
viral genome or elements thereof as genetic vector
C12N2730/10044
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N2730/10045
Special targeting system for viral vectors
C12N2730/10051
Methods of production or purification of viral material
C12N2730/10052
relating to complementing cells and packaging systems for producing virus or viral particles
C12N2730/10061
Methods of inactivation or attenuation
C12N2730/10062
by genetic engineering
C12N2730/10063
by chemical treatment
C12N2730/10064
by serial passage
C12N2730/10071
Demonstrated in vivo effect
C12N2730/10088
For redistribution
C12N2730/10111
Orthohepadnavirus
C12N2730/10121
Viruses as such
C12N2730/10122
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2730/10123
Virus like particles [VLP]
C12N2730/10131
Uses of virus other than therapeutic or vaccine
C12N2730/10132
Use of virus as therapeutic agent, other than vaccine
C12N2730/10133
Use of viral protein as therapeutic agent other than vaccine
C12N2730/10134
Use of virus or viral component as vaccine
C12N2730/10141
Use of virus, viral particle or viral elements as a vector
C12N2730/10142
virus or viral particle as vehicle
C12N2730/10143
viral genome or elements thereof as genetic vector
C12N2730/10144
Chimeric viral vector comprising heterologous viral elements for production of another viral vector
C12N2730/10145
Special targeting system for viral vectors
C12N2730/10151
Methods of production or purification of viral material
C12N2730/10152
relating to complementing cells and packaging systems for producing virus or viral particles
C12N2730/10161
Methods of inactivation or attenuation
C12N2730/10162
by genetic engineering
C12N2730/10163
by chemical treatment
C12N2730/10164
by serial passage
C12N2730/10171
Demonstrated in vivo effect
C12N2730/10188
For redistribution
Industries
Overview
Organizations
People
Information
Impact
Please log in for detailed analytics